Dennis Karl Huang

CIK: 0001641217

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)2 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RARE

Ultragenyx Pharmaceutical Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

RARE
Ultragenyx Pharmaceutical Inc.
Apr 16, 2026
Award(A)
Direct
23.1K shares-
RARE
Ultragenyx Pharmaceutical Inc.
Mar 2, 2026
Tax Payment(F)
Direct
999 shares at avg. $23.39$23K
RARE
Ultragenyx Pharmaceutical Inc.
Mar 1, 2026
Award(A)
Direct
11.1K shares-
RARE
Ultragenyx Pharmaceutical Inc.
Mar 3, 2025
Tax Payment(F)
Direct
1.3K shares at avg. $42.92$58K
RARE
Ultragenyx Pharmaceutical Inc.
Mar 1, 2025
Award(A)
Direct
14.5K shares-
RARE
Ultragenyx Pharmaceutical Inc.
Mar 1, 2025
Award(A)
Direct
18.4K shares-

		Type	Shares	Price		Ownership
Apr 16, 2026	RARE Ultragenyx Pharmaceutical Inc.	Award(A)	23,116	-	$0	Direct
Mar 2, 2026	RARE Ultragenyx Pharmaceutical Inc.	Tax Payment(F)	999	$23.39	$23,367	Direct
Mar 1, 2026	RARE Ultragenyx Pharmaceutical Inc.	Award(A)	11,137	-	$0	Direct
Mar 3, 2025	RARE Ultragenyx Pharmaceutical Inc.	Tax Payment(F)	1,348	$42.92	$57,856	Direct
Mar 1, 2025	RARE Ultragenyx Pharmaceutical Inc.	Award(A)	14,494	-	-	Direct
Mar 1, 2025	RARE Ultragenyx Pharmaceutical Inc.	Award(A)	18,443	-	-	Direct

1-6 of 6 transactions

About Huang Dennis Karl

Huang Dennis Karl (SEC CIK 0001641217) files insider reports with the SEC as Officer of Ultragenyx Pharmaceutical Inc. (RARE).

Signal8 holds 3 ownership filings by Huang Dennis Karl, all Form 4s, filed between Mar 4, 2025 and Apr 20, 2026. Those filings report 6 transactions, from Mar 1, 2025 to Apr 16, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Huang Dennis Karl's filings is in NOVATO, CA.

Recent filings by Huang Dennis Karl

Apr 16, 2026: Grant or award of RARE shares (Form 4, code A).
Mar 2, 2026: Tax withholding of RARE shares (Form 4, code F).
Mar 1, 2026: Grant or award of RARE shares (Form 4, code A).
Mar 3, 2025: Tax withholding of RARE shares (Form 4, code F).
Mar 1, 2025: Grants or awards of RARE shares (2 lines, Form 4, code A).

Other insiders filing for Ultragenyx Pharmaceutical Inc. (RARE)

Horn Howard, Chief Financial Officer
Huizenga Theodore Alan, SVP, Chief Accounting Officer
Parschauer Karah Herdman, EVP and Chief Legal Officer
Sanders Corazon (Corsee) D., Director
Fust Matthew K, Director
SULIMAN SHEHNAAZ, Director

How to read Form 4 transaction codes